Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132397 | 0.91 | MAPT (0.59) | ALDH1A1MAPTLMNAKCNJ1SMN1; SMN2 | |
| SCHEMBL5127223 | 0.89 | MAPT (0.53) | ALDH1A1MAPTLMNAKCNJ1SMN1; SMN2 | |
| SCHEMBL5132635 | 0.84 | SIRT6 (0.62) | ALDH1A1MAPTLMNASMN1; SMN2SIRT6 | |
| SCHEMBL5129427 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNAKCNJ1SMN1; SMN2 | |
| SCHEMBL21275120 | 0.83 | L3MBTL1 (0.53) | ALDH1A1MAPTLMNAKCNJ1SMN1; SMN2 | |
| SCHEMBL19419599 | 0.80 | ALDH1A1 (0.69) | ALDH1A1MAPTLMNAKCNJ1SMN1; SMN2 | |
| SCHEMBL4437381 | 0.80 | MAPT (0.45) | ALDH1A1MAPTLMNAKCNJ1SMN1; SMN2 | |
| SCHEMBL18099304 | 0.79 | MAPT (0.45) | ALDH1A1MAPTLMNAKCNJ1SMN1; SMN2 | |
| SCHEMBL4434559 | 0.79 | MAPT (0.45) | ALDH1A1MAPTLMNAKCNJ1SMN1; SMN2 | |
| SCHEMBL14032704 | 0.79 | KDM4E (0.45) | ALDH1A1MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | EPHB4, EPHB1, NME2 | ALDH1A1 1143/4885MAPT 3593/4885LMNA 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.